Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2016

Open Access 01-12-2016 | Research article

Thoracic perfusion of recombinant human endostatin (Endostar) combined with chemotherapeutic agents versus chemotherapeutic agents alone for treating malignant pleural effusions: a systematic evaluation and meta-analysis

Authors: Rong Biaoxue, Cai Xiguang, Liu Hua, Gao Wenlong, Yang Shuanying

Published in: BMC Cancer | Issue 1/2016

Login to get access

Abstract

Background

Endostar is a new endogenous angiogenic inhibitor with implicated anti-tumor activity. This study was to investigate whether thoracic perfusion of Endostar could be used to control malignant pleural effusions (MPE).

Methods

We searched the databases of MEDLINE, Web of Science, EMBASE, Goggle, Cochrance Library and CNKI to select the studies regarding the efficacy of Endostar to treat MPE. A total of 13 randomised controlled trials (RCTs) with 1066 patients were included.

Results

The overall response rate (ORR) (P < 0.001; odds ratio = 3.58) and disease control rate (DCR) (P < 0.001; odds ratio = 2.97) of Endostar combined with chemotherapeutic agents were significantly higher than those of chemotherapeutic agents alone. In addition, Endostar combined treatment remarkably promoted quality of life (QOL) of patients (P < 0.001; odds ratio = 3.04) compared with that of chemotherapeutic agents alone. Moreover, Endostar combined treatment did not have an impact on the incidence of adverse reactions (AEs) (P < 0.05).

Conclusions

The efficacy of Endostar combined chemotherapeutic agents was superior to chemotherapeutic agents alone through thoracic perfusion in treating MPE, which indicated that Endostar could be an effective agent for controlling MPE.
Literature
1.
Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–32.CrossRefPubMed
2.
Zarogoulidis K, Zarogoulidis P, Darwiche K, Tsakiridis K, Machairiotis N, Kougioumtzi I, et al. Malignant pleural effusion and algorithm management. J Thorac Dis. 2013;5 Suppl 4:S413–9.PubMedPubMedCentral
3.
Jones DR, Taylor MD, Petroni GR, Shu J, Burks SG, Daniel TM, et al. Phase I trial of intrapleural docetaxel administered through an implantable catheter in subjects with a malignant pleural effusion. J Thorac Oncol. 2010;5(1):75–81.CrossRefPubMed
4.
Stathopoulos GT, Kalomenidis I. Malignant pleural effusion: tumor-host interactions unleashed. Am J Respir Crit Care Med. 2012;186(6):487–92.CrossRefPubMed
5.
Thomas R, Francis R, Davies HE, Lee YC. Interventional therapies for malignant pleural effusions: the present and the future. Respirology. 2014;19(6):809–22.CrossRefPubMed
6.
O’Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 1997;88(2):277–85.CrossRefPubMed
7.
Sun Y, Wang JW, Liu YY, Yu QT, Zhang YP, Li K, et al. Long-term results of a randomized, double-blind, and placebo-controlled phase III trial: Endostar (rh-endostatin) versus placebo in combination with vinorelbine and cisplatin in advanced non-small cell lung cancer. Thorac Cancer. 2013;4(4):440–8.CrossRef
8.
Rong B, Yang S, Li W, Zhang W, Ming Z. Systematic review and meta-analysis of Endostar (rh-endostatin) combined with chemotherapy versus chemotherapy alone for treating advanced non-small cell lung cancer. World J Surg Oncol. 2012;10:170.CrossRefPubMed
9.
Song HF, Liu XW, Zhang HN, Zhu BZ, Yuan SJ, Liu SY, et al. Pharmacokinetics of His-tag recombinant human endostatin in Rhesus monkeys. Acta Pharmacol Sin. 2005;26(1):124–8.CrossRefPubMed
10.
Wang J, Sun Y, Liu Y, Yu Q, Zhang Y, Li K, et al. Results of randomized, multicenter, double-blind phase III trial of rh-endostatin (YH-16) in treatment of advanced non-small cell lung cancer patients. Zhongguo fei ai za zhi. 2005;8(4):283–90.PubMed
11.
Xiao L, Yang S, Hao J, Yuan X, Luo W, Jiang L, et al. Endostar attenuates melanoma tumor growth via its interruption of b-FGF mediated angiogenesis. Cancer Lett. 2015;359(1):148–54.CrossRefPubMed
12.
Ling Y, Yang Y, Lu N, You QD, Wang S, Gao Y, et al. Endostar, a novel recombinant human endostatin, exerts antiangiogenic effect via blocking VEGF-induced tyrosine phosphorylation of KDR/Flk-1 of endothelial cells. Biochem Biophys Res Commun. 2007;361(1):79–84.CrossRefPubMed
13.
Cao H, Liu J, Lewith GT. Traditional Chinese Medicine for treatment of fibromyalgia: a systematic review of randomized controlled trials. J Altern Complement Med. 2010;16(4):397–409.CrossRefPubMedPubMedCentral
14.
Cirocchi R, D’Ajello F, Trastulli S, Santoro A, Di Rocco G, Vendettuoli D, et al. Meta-analysis of thyroidectomy with ultrasonic dissector versus conventional clamp and tie. World J Surg Oncol. 2010;8:112.CrossRefPubMedPubMedCentral
15.
Liu W, Ha M, Ying N, Li J. Efficacy of intrapleural infusion of endostar combined with cisplatin in the treatment of malignant pleural effusion. Shandong Med J. 2010;50(8):79–80.
16.
Mao L, Liao G, Wang H, Liu P, Xie G. Observation of clinical efficacy of endostar combined with DDP on malignant bloody pleural effusion. Med J Nat Defend Forces Southwest Chin. 2011;21(7):723–5.
17.
Li G, Zhao J-D, Li Y, Di J, Jiang J, Zhao J. Application of endostar combined with bleomycin in the treatment of malignant pleural effusion. Chin J N Drugs. 2011;20(16):1544–7.
18.
Ma E, Zou L, Yuan D. Clinical observation on the treatment of malignant pleural effusion with endostar and combined with chemotherapy. Chin Med Pharmcol. 2012;2(15):52–3.
19.
Yao Q, Lin Q, Liu S, Shen D, Lin F, Mao W. Efficacy of intrapleural infusion of endostar combined with nedaplatin in the treatment of malignant pleural effusion. J Basic Clin Oncol. 2012;25(6):492–4.
20.
Zheng Q. A comparision between intrapleural injection of cisplatin combined with endostar and cisplatin alone in the treatment for malignant pleural effusion. J Chin Oncol. 2013;19(5):386–9.
21.
Kang Y, Min J, Fu J, Ma N, Li N, Shan Y, et al. Therapeutic effect of endostar combined with cisdiammi dichloride platinum on malignant pleural effusion. Mod Oncol. 2013;21(11):2485–7.
22.
Wen J, Ge W, Li G, Peng Y, Chen G, Wang J. Clinical observation of pleural hyperthermic perfusion chemotherapy with Endostar and Lobaplatin for treatment of malignant pleural effusion. BME & Clin Med. 2014;18(6):540–3.
23.
Yue G, Bai Y, Ma H, Li N, Yang W, Shi L, et al. Analysis of efficacy and security cisplatin endostar in the treatment of non-small cell lung cancer bloody pleural effusion. Mod Diagn Treat. 2014;25(11):2478–80.
24.
Tu J, Huang S, Wang M. Clinical efficacy of pleural perfusion with recombinant human endostatin combined with cisdiammi dichloride platinum for advanced non-small cell lung cancer patients with malignant pleural effusion. Pract J Cancer. 2014;29(12):1592–4.
25.
Xu J, Qi D, Li X, Wang R. Efficacy of recombinant human endostatin (Endostar) combined with chemotherapy for malignant pleural effusion in non-small cell lung cancer patients. Chin J Clin Oncol. 2014;41(24):1573–6.
26.
Wen X. Clinical observation of recombinant Endostatin combined with the treatment of malignant pleural effusion of non-small cell lung cancer. World Latest Med Info. 2015;15(49):6–7.
27.
Hu X, Wang H, Zhang C, Liu P, Wang Y, Li J, et al. Clinical study on intra-thoracic chemotherapy with recombinant human endostain combined with cisplatin in treatment of patients with malignant pleural effusion. Clin Med J. 2015;13(3):23–7.
28.
Rong B, Zhao C, Gao W, Yang S. Matrine promotes the efficacy and safety of platinum-based doublet chemotherapy for advanced non-small cell lung cancer. Int J Clin Exp Med. 2015;8(9):14701–17.PubMedPubMedCentral
29.
Tan C, Sedrakyan A, Browne J, Swift S, Treasure T. The evidence on the effectiveness of management for malignant pleural effusion: a systematic review. Eur J Cardiothorac Surg. 2006;29(5):829–38.CrossRefPubMed
30.
Morgensztern D, Waqar S, Subramanian J, Trinkaus K, Govindan R. Prognostic impact of malignant pleural effusion at presentation in patients with metastatic non-small-cell lung cancer. J Thorac Oncol. 2012;7(10):1485–9.CrossRefPubMed
31.
Du N, Li X, Li F, Zhao H, Fan Z, Ma J, et al. Intrapleural combination therapy with bevacizumab and cisplatin for non-small cell lung cancermediated malignant pleural effusion. Oncol Rep. 2013;29(6):2332–40.PubMed
32.
Huang C, Wang X, Wang J, Lin L, Liu Z, Xu W, et al. Incidence and clinical implication of tumor cavitation in patients with advanced non-small cell lung cancer induced by Endostar, an angiogenesis inhibitor. Thorac Cancer. 2014;5(5):438–46.CrossRefPubMedPubMedCentral
33.
Shang L, Zhao J, Wang W, Xiao W, Li J, Li X, et al. Inhibitory effect of endostar on lymphangiogenesis in non-small cell lung cancer and its effect on circulating tumor cells. Chin J Lung Cancer. 2014;17(10):722–9.
34.
Ma X, Yao Y, Yuan D, Liu H, Wang S, Zhou C, et al. Recombinant human endostatin endostar suppresses angiogenesis and lymphangiogenesis of malignant pleural effusion in mice. PLoS One. 2012;7(12):e53449.CrossRefPubMedPubMedCentral
Metadata
Title
Thoracic perfusion of recombinant human endostatin (Endostar) combined with chemotherapeutic agents versus chemotherapeutic agents alone for treating malignant pleural effusions: a systematic evaluation and meta-analysis
Authors
Rong Biaoxue
Cai Xiguang
Liu Hua
Gao Wenlong
Yang Shuanying
Publication date
01-12-2016
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2016
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-016-2935-4

Other articles of this Issue 1/2016

BMC Cancer 1/2016 Go to the issue

Research article

Critical weight loss predicts poor prognosis in nasopharyngeal carcinoma

Research article

Binimetinib inhibits MEK and is effective against neuroblastoma tumor cells with low NF1 expression

Research article

MiRNA-146b-5p upregulates migration and invasion of different Papillary Thyroid Carcinoma cells

Research article

A pharmacogenetic pilot study reveals MTHFR, DRD3, and MDR1 polymorphisms as biomarker candidates for slow atorvastatin metabolizers

Research article

Clinical application of genomic profiling to find druggable targets for adolescent and young adult (AYA) cancer patients with metastasis

Research article

Self-sampling in cervical cancer screening: comparison of a brush-based and a lavage-based cervicovaginal self-sampling device
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits